Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03230526
PHASE2

Identification of a Biomarker Predictive of Evolution of Parkinson Disease

Sponsor: Nantes University Hospital

View on ClinicalTrials.gov

Summary

Phase II, Open-labeled, Prospective, Multi-center study of assessing the link between microglial activation and dopaminergic denervation kinetics in the early stage of Parkinson disease, by using the imaging of \[18F\]DPA-714 a new ligand of Translocator Protein-18 kDa (TSPO) by Positron Emission Tomography (PET).

Official title: Brain Microglial Activation in the Early Stage of the Parkinson's Disease: a Predictive Biomarker of the Evolution?

Key Details

Gender

All

Age Range

40 Years - 67 Years

Study Type

INTERVENTIONAL

Enrollment

31

Start Date

2018-04-16

Completion Date

2024-05-06

Last Updated

2024-04-25

Healthy Volunteers

No

Interventions

DRUG

[18F]DPA-714 PET scan

One PET scan using \[18F\]DPA-714 is done at M2 between two \[123I\]FP-CIT scan (DaTscan) done at M1 and M23. Neuropsychological assessment is done at M0, M18 and M24

Locations (4)

CHU de Nantes

Nantes, France

Centre Eugène Marquis

Rennes, France

CHU de Rennes

Rennes, France

CHU de Tours

Tours, France